Next Article in Journal
Role of Lipopolysaccharide in Protecting OmpT from Autoproteolysis during In Vitro Refolding
Previous Article in Journal
Profiling and Role of Bioactive Molecules from Puntius sophore (Freshwater/Brackish Fish) Skin Mucus with Its Potent Antibacterial, Antiadhesion, and Antibiofilm Activities
Open AccessArticle

Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076)

1
Research Laboratory, ILDONG Pharmaceutical Co., Ltd., Hwaseong 18449, Korea
2
Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(6), 919; https://doi.org/10.3390/biom10060919
Received: 27 March 2020 / Revised: 4 June 2020 / Accepted: 15 June 2020 / Published: 17 June 2020
Although bevacizumab (Avastin®) has been approved as an antiangiogenic agent against some cancers, the efficacy is transient and unsatisfactory in other cancers most likely owing to the presence of alternative proangiogenic factors. Therefore, simultaneous blocking of several proangiogenic factors may be a promising strategy for antiangiogenic cancer therapeutics. Accordingly, neuropilin-1 (NRP1) is an attractive target because it serves as a multifunctional receptor for the vascular endothelial growth factor (VEGF) family. Here, we aimed to generate and test an anti-VEGFA and anti-NRP1 dual-targeting bispecific antibody (named as IDB0076) by genetic fusion of an NRP1-targeting peptide to the C-terminus of the bevacizumab heavy chain. Similar to the parental antibody (bevacizumab), IDB0076 suppressed VEGFA-induced migration of human endothelial cells. In contrast, IDB0076 inhibited endothelial-cell migration induced by other angiogenesis growth factors and manifested a more potent antitumor activity than that of bevacizumab in a murine tumor xenograft model. When toxicity was preliminarily evaluated in cynomolgus monkeys, IDB0076 showed no substantial adverse effects, e.g., the absence of noticeable nephrotoxicity, which has previously been documented for the combination therapy of bevacizumab and an anti-NRP1 antibody. Thus, VEGFA-and-NRP1 dual-targeting bispecific antibody IDB0076 may be a potent and safe anticancer agent worthy of further preclinical and clinical studies. View Full-Text
Keywords: Neuropilin-1; Vascular endothelial growth factor A; IDB0076; angiogenesis; bispecific antibody Neuropilin-1; Vascular endothelial growth factor A; IDB0076; angiogenesis; bispecific antibody
Show Figures

Figure 1

MDPI and ACS Style

Ko, J.-H.; Kwon, H.-S.; Kim, B.; Min, G.; Shin, C.; Yang, S.-W.; Lee, S.W.; Lee, Y.; Hong, D.; Kim, Y.-S. Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076). Biomolecules 2020, 10, 919.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop